Antibody Gene Therapy Mitigates Adverse Immunological Effects of 3,4‐Methylenedioxymethamphetamine (MDMA) in Male BALB/c Mice
Chris Bolden, Cameron Tilley, Charles E Hay, Eric Peterson
The FASEB Journal April 1, 2020 DOI: 10.1096/fasebj.2020.34.s1.05528 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | MDMA |
| Key findings | MDMA causes immunosuppression in the periphery and a proinflammatory response in the central nervous system. |
Abstract
3,4‐Methylenedioxymethamphetamine (MDMA) is a popular recreational psychostimulant and hallucinogen typically used in “rave” settings. Despite the “positive” feelings sometimes associated with its use, there are toxicities that accompany its use. In the periphery, MDMA causes immunosuppression that can make users more susceptible to infection. Conversely, in the CNS MDMA initiates a proinflammatory response that is linked to glial activation and the subsequent overproduction of cytokines, chemokines, and even cellular adhesion molecules. A treatment that could potentially mitigate these effects would be beneficial.